Specimen index
Peptide Database
14 peptides — filtered results
BPC-157
PreclinicalBody Protection Compound 157 · PL 14736
BPC-157 is a 15-amino-acid peptide fragment derived from human gastric juice. It is one of the most extensively researched peptides for tissue repair, demonstrating accelerated healing of tendons, ligaments, muscle, bone, and gut lining in animal models. It appears to upregulate growth hormone receptors and promote angiogenesis at injury sites.
C₆₂H₉₈N₁₆O₂₂ · 1419.55 Da
Carnosine
PreclinicalBeta-Alanyl-L-Histidine · L-Carnosine
Carnosine is a naturally occurring dipeptide (β-alanyl-L-histidine) found at high concentrations in skeletal muscle and the brain. It acts as a pH buffer in muscle (reducing acidosis during high-intensity exercise), a powerful antioxidant, an antiglycation agent (preventing protein-sugar crosslinking), and a chelator of zinc and copper. Research explores its role in aging, cognitive decline, autism, and exercise performance.
Cholecystokinin
PreclinicalCCK · CCK-8
Cholecystokinin (CCK) is a peptide hormone produced by duodenal I-cells and neurons in the CNS. It triggers gallbladder contraction, pancreatic enzyme secretion, and potently suppresses appetite via vagal nerve CCK1 receptors. In the brain, CCK neurons modulate anxiety, pain, memory consolidation, and dopamine release. CCK antagonists are studied for anxiety and pain; CCK agonists for obesity and eating disorders.
CRH
PreclinicalCorticotropin-Releasing Hormone · Corticotropin-Releasing Factor
CRH is a 41-amino-acid neuropeptide produced in the hypothalamus that drives the HPA axis stress response. It stimulates ACTH release from the anterior pituitary, ultimately triggering cortisol secretion. Beyond stress regulation, CRH receptors (CRHR1, CRHR2) are distributed throughout the brain and gut, mediating anxiety, depression, immune function, and GI motility. CRH antagonists are under development for anxiety, depression, and irritable bowel syndrome.
Dihexa
PreclinicalN-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408
Dihexa is a small peptide derived from angiotensin IV that acts as a potent agonist at the HGF/c-Met receptor system, which mediates synaptogenesis — the formation of new synaptic connections. Animal studies suggest it may be several orders of magnitude more potent than BDNF at promoting synapse formation. Research focuses on Alzheimer's disease, cognitive decline, and traumatic brain injury.
Enkephalins
PreclinicalLeu-Enkephalin · Met-Enkephalin
Enkephalins are endogenous opioid pentapeptides (Met-enkephalin and Leu-enkephalin) acting as natural ligands for delta and mu opioid receptors. They modulate pain, mood, reward, and immune function. Low-dose naltrexone (LDN) works partly by transiently blocking opioid receptors to upregulate enkephalin production. Methionine enkephalin (met-enkephalin) has shown immune-modulating and anti-tumor properties in research, particularly for HIV and cancer.
Galanin
PreclinicalGAL
Galanin is a 29-30 amino acid neuropeptide widely distributed throughout the CNS and peripheral nervous system. It modulates memory, mood, pain, seizures, appetite, and sleep via three receptor subtypes (GALR1–3). Research focuses on its roles in Alzheimer's disease (galanin hyperinnervation of cholinergic neurons), depression, epilepsy, and eating behavior. Both agonists and antagonists have therapeutic potential depending on the target condition.
IGF-2
PreclinicalInsulin-like Growth Factor 2 · Somatomedin A
IGF-2 is a 67-amino-acid peptide growth factor closely related to IGF-1, primarily active during fetal and neonatal development. In adults, research highlights its potent cognitive effects — IGF-2 administration after training enhances long-term memory consolidation in rodents by a remarkable degree, acting through IGF2R and mannose-6-phosphate receptors in the hippocampus. It has also emerged as a candidate for treating cognitive deficits in aging and neurodegenerative disease.
Neuropeptide Y
PreclinicalNPY
Neuropeptide Y (NPY) is a 36-amino-acid peptide and the most abundant neuropeptide in the mammalian CNS, acting through Y1–Y6 receptors. It is a potent orexigenic signal (stimulating appetite and fat storage), anxiolytic agent, vasoconstrictor, and regulator of circadian rhythms. Paradoxically, peripheral NPY promotes fat accumulation while central NPY drives food intake — making it a complex but high-priority metabolic research target.
Neurotensin
PreclinicalNT · NTS
Neurotensin is a 13-amino-acid neuropeptide found in the brain and GI tract. Centrally, it modulates dopamine circuits, acts as an endogenous antipsychotic-like agent, and is analgesic. Peripherally, it inhibits gastric acid secretion, stimulates pancreatic secretion, and promotes fat absorption. Research explores neurotensin analogs for pain, schizophrenia, Parkinson's disease, and metabolic regulation.
Orexin A
PreclinicalHypocretin-1 · OXA
Orexin A (Hypocretin-1) is a 33-amino-acid neuropeptide produced exclusively by lateral hypothalamic neurons. It promotes wakefulness, arousal, and energy expenditure via OX1R and OX2R receptors, and its deficiency (due to autoimmune destruction of orexin neurons) is the cause of narcolepsy with cataplexy. Orexin receptor antagonists (suvorexant, lemborexant) are approved for insomnia; orexin agonists are under development for narcolepsy.
P21
PreclinicalP21 cognitive peptide
P21 is a peptide fragment derived from CNTF (Ciliary Neurotrophic Factor) designed to activate the STAT3 signaling pathway, which promotes neurogenesis and cognitive function. Animal research demonstrates improved spatial memory, increased hippocampal neurogenesis, and enhanced BDNF expression. It is studied as a non-cytokine CNTF functional mimetic without the systemic side effects of full-length CNTF.
Pinealon
PreclinicalEDR peptide · Glu-Asp-Arg
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is characterized as a pineal gland cytoprotective peptide that penetrates the blood-brain barrier and acts as a transcription factor, regulating gene expression in neuronal cells. Research suggests neuroprotective, antioxidant, and cognition-preserving effects, particularly in aging and hypoxic conditions.
Substance P
PreclinicalSP · NK1 ligand
Substance P is an 11-amino-acid neuropeptide of the tachykinin family and a primary neurotransmitter of pain signaling in the spinal cord. It binds NK1 receptors to mediate neurogenic inflammation, pain hypersensitivity, and emotional processing. NK1 antagonists have been developed for pain, depression (aprepitant), and nausea. Research also implicates substance P in wound healing, immune activation, and neuroinflammation.